CoChat
Sign Up
Cited by 1,166

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Translating cell biology into therapeutic advances in Alzheimer's disease

Selkoe, Dennis J.·1999·Nature
DOI 10.1038/399a023
Open this paper in CoChat — free account

Abstract

Studies of the molecular basis of Alzheimer's disease exemplify the increasingly blurred distinction between basic and applied biomedical research. The four genes so far implicated in familial Alzheimer's disease have each been shown to elevate brain levels of the self-aggregating amyloid-beta protein, leading gradually to profound neuronal and glial alteration, synaptic loss and dementia. Progress in understanding this cascade has helped to identify specific therapeutic targets and provides a model for elucidating other neurodegenerative disorders.

Overview

Integrity signals

Registry

Crossref · 10.1038/399a023

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 76

  1. Dickson, D. W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56, 321–339 (1997). · DOI · Paper page
  2. Yamaguchi, H., Nakazato, Y., Hirai, S., Shoji, M. & Harigaya, Y. Electron micrograph of diffuse plaques: initial stage of senile plaque formation in the Alzheimer brain. Am. J. Pathol. 135, 593–597 (1989).
  3. Goedert, M., Trojanowski, J. Q. & Lee, V. M.-Y. in The Molecular and Genetic Basis of Neurological Disease, 2nd edn (eds Rosenberg, R. N., Prusiner, S. B., DiMauro, S. & Barchi, R. L.) 613–627 (Butterworth-Heinemann, Boston, 1996).
  4. Saunders, A. M. et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467–1472 (1993). · DOI · Paper page
  5. Rogaev, E. I. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775–778 (1995). · DOI · Paper page
  6. Blacker, D. et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 19, 357–360 (1998). · DOI · Paper page
  7. Spillantini, M. G. et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737–7741 (1998). · DOI · Paper page
  8. Poorkaj, P. et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815–825 (1998). · DOI · Paper page
  9. Goedert, M. Tau mutations cause frontotemporal dementias. Neuron 21, 955–958 (1998). · DOI · Paper page
  10. Glenner, G. G. & Wong, C. W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131–1135 (1984). · DOI · Paper page
  11. Selkoe, D. J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10, 373–403 (1994). · DOI
  12. Zheng, H. et al. β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81, 525–531 (1995). · DOI
  13. Perez, R. G., Zheng, H., Van der Ploeg, L. H. & Koo, E. H. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J. Neurosci. 17, 9407–9414 (1997). · DOI
  14. Wasco, W. et al. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid β-protein precursor. Proc. Natl Acad. Sci. USA 89, 10758–10762 (1992). · DOI
  15. Slunt, H. H. et al. Expression of a ubiquitous, cross-reactive homologue of the mouse β-amyloid precursor protein (APP). J. Biol. Chem. 269, 2637–2644 (1994). · DOI
  16. Sisodia, S. S. β-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci. USA 89, 6075–6079 (1992). · DOI
  17. Buxbaum, J. D. et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 27765–27767 (1998). · DOI
  18. Busciglio, J., Gabuzda, D. H., Matsudaira, P. & Yankner, B. A. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl Acad. Sci. USA 90, 2092–2096 (1993). · DOI · Paper page
  19. Seubert, P. et al. Secretion of β-amyloid precursor protein cleaved at the amino-terminus of the β-amyloid peptide. Nature 361, 260–263 (1993). · DOI
  20. Levitan, D. & Greenwald, I. Facilitation of lin-12-mediated signalling by sel-12,a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377, 351–354 (1995). · DOI
  21. Levitan, D. et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans . Proc. Natl Acad. Sci. USA 93, 14940–14944 (1996). · DOI
  22. Baumeister, R. et al. Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans notch signalling independently of proteolytic processing. Genes Function 1, 149–159 (1997). · DOI
  23. Zhou, J. et al. Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport 8, 2085–2090 (1997). · DOI
  24. Yu, G. et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J. Biol. Chem. 273, 16470–16475 (1998). · DOI
  25. Wong, P. et al. Presenilin 1 is required for Notch 1 and D111 expression in the paraxial mesoderm. Nature 397, 288 (1997). · DOI
  26. Shen, J. et al. Skeletal and CNS defects in presenilin-1 deficient mice. Cell 89, 629–639 (1997). · DOI · Paper page
  27. Qian, S. et al. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron 20, 611–617 (1998). · DOI
  28. Thinakaran, G. et al. Endoprotreolysis of presenilin 1 and accumulation of processed derivatives in vivo . Neuron 17, 181–190 (1996). · DOI
  29. Podlisny, M. B. et al. Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol. Dis. 3, 325–337 (1997). · DOI
  30. Li, X. & Greenwald, I. Additional evidence for an eight-transmembrane-domain topology for Caenorhabditis elegans and human presenilins. Proc. Natl Acad. Sci. USA 95, 7109–7114 (1998). · DOI
  31. Thinakaran, G. et al. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J. Biol. Chem. 272, 28415–28422 (1997). · DOI
  32. Steiner, H. et al. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273, 32322–32331 (1998). · DOI
  33. Capell, A. et al. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J. Biol. Chem. 273, 3205–3211 (1998). · DOI
  34. Zhang, J. et al. Subcellular distribution and turnover of presenilins in transfected cells. J. Biol. Chem. 273, 12436–12442 (1998). · DOI
  35. Tomita, T. et al. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Abeta42. J. Biol. Chem. 273, 21153–21160 (1998). · DOI
  36. Selkoe, D. J. Alzheimer's disease: genotypes, phenotype, and treatments. Science 275, 630–631 (1997). · DOI
  37. Mann, D. M. et al. Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. Acta Neuropathol. (Berl.) 90, 472–477 (1995). · DOI
  38. Levy, E. et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248, 1124–1126 (1990). · DOI
  39. Hendriks, L. et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nature Genet. 1, 218–221 (1992). · DOI
  40. Schmechel, D. E. et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 9649–9653 (1993). · DOI · Paper page
  41. Rebeck, G. W., Reiter, J. S., Strickland, D. K. & Hyman, B. T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11, 575–580 (1993). · DOI · Paper page
  42. Evans, K. C., Berger, E. P., Cho, C.-G., Weisgraber, K. H. & Lansbury, P. T. Jr Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 763–767 (1995). · DOI · Paper page
  43. Hardy, J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc. Natl Acad. Sci. USA 94, 2095–2097 (1997). · DOI
  44. Holcomb, L. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4, 97–100 (1998). · DOI · Paper page
  45. Thinakaran, G. et al. Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiol. Dis. 4, 438–453 (1998). · DOI
  46. Xia, W. et al. Presenilin 1 regulates the processing APP C-terminal fragments and the generation of amyloid β-protein in ER and Golgi. Biochemistry 37, 16465–16471 (1998). · DOI
  47. Weidemann, A. et al. Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and β-amyloid precursor protein. Nature Med. 3, 328–332 (1997). · DOI
  48. Xia, W., Zhang, J., Perez, R., Koo, E. H. & Selkoe, D. J. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer's disease. Proc. Natl Acad. Sci. USA 94, 8208–8213 (1997). · DOI
  49. Wolfe, M. S. et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and β-secretase activity. Nature 398, 513–517 (1999). · DOI
  50. De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387–390 (1998). · DOI · Paper page
  51. Schroeter, E. H., Kisslinger, J. A. & Kopan, R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393, 382–386 (1998). · DOI
  52. Brockhaus, M. et al. Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. NeuroReport 9, 1481–1486 (1998). · DOI
  53. Eikelenboom, P., Zhan, S. S., van Gool, W. A. & Allsop, D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15, 447–450 (1994). · DOI
  54. Rogers, J. et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging 17, 681–686 (1996). · DOI
  55. Rogers, J. et al. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 89, 10016–10020 (1992). · DOI · Paper page
  56. Itagaki, S., Akiyama, H., Saito, H. & McGeer, P. L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645, 78–84 (1994). · DOI
  57. Behl, C., Davis, J. B., Lesley, R. & Schubert, D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77, 817–827 (1994). · DOI · Paper page
  58. Harris, M. E., Hensley, K., Butterfield, D. A., Leedle, R. A. & Carney, J. M. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131, 193–202 (1995). · DOI
  59. Mattson, M. P. et al. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 379–389 (1992). · DOI
  60. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G. & Cotman, C. W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676–1687 (1993). · DOI · Paper page
  61. Lorenzo, A. & Yankner, B. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl Acad. Sci. USA 91, 12243–12247 (1994). · DOI · Paper page
  62. Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (1996). · DOI · Paper page
  63. Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. Jr Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119–125 (1997). · DOI
  64. Walsh, D. M. et al. Amyloid β-protein fibrillogenesis: detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364–22374 (1997). · DOI
  65. Wolozin, B. et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274, 1710–1713 (1996). · DOI
  66. Miller, D. L., Papayannopoulos, I. A., Styles, J. & Bobin, S. A. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301, 41–52 (1993). · DOI · Paper page
  67. Roher, A. E. et al. β-amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease. Proc. Natl Acad. Sci. USA 90, 10836–10840 · DOI · Paper page
  68. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693–4697 (1993). · DOI · Paper page
  69. Yamazaki, T., Koo, E. H. & Selkoe, D. J. Trafficking of cell-surface amyloid β-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J. Cell Sci. 109, 999–1008 (1996). · DOI
  70. Yamazaki, T., Selkoe, D. J. & Koo, E. H. Trafficking of cell surface β-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J. Cell Biol. 129, 431–442 (1995). · DOI
  71. Koo, E. H. & Squazzo, S. Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386–17389 (1994). · DOI · Paper page
  72. Wilde-Bode, C. et al. Intracellular generation and accumulation of amyloid β-peptide terminating at amino acid 42. J. Biol. Chem. 272, 16085–16088 (1997). · DOI · Paper page
  73. Cook, D. G. et al. Alzheimer's Aβ (1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nature Med. 3, 1021–1023 (1997). · DOI
  74. Chyung, A. S. C., Greenberg, B. D., Cook, D. G., Doms, R. W. & Lee, V. M.-Y. Novel β-secretase cleavage of β-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J. Cell Biol. 138, 671–680 (1997). · DOI
  75. Hartmann, T. et al. Distinct sites of intracellular production for Alzheimer's disease Aβ-40/42 amyloid peptides. Nature Med. 3, 1016–1020 (1997). · DOI
  76. Lee, S. J. et al. A detergent-insoluble membrane compartment contains Aβ in vivo. Nature Med. 4, 730–734 (1998). · DOI

Cited by

Sorted by citations

Metadata

Authors
Selkoe, D. J.
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
1999-06
Volume
399
Issue
6738
Pages
A23-A31
ISSN
  • 0028-0836
  • 1476-4687
DOI
10.1038/399a023
Cited by
1,166
References
24
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review